Investigational studies utilising positron emission tomography and scintigraphy have shown that it is possible to detect HER2 and ER in vivo (Linden et al, 2006; Perik et al, 2006), and an increased need to visualise these tumour targets is apparent as targeted therapies against specific molecules in cancer are rapidly developing. This evidence concerns the gene ERBB2 and cancer.